PTC Therapeutics
PTCT
202 hedge funds and large institutions have $2.94B invested in PTC Therapeutics in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 67 increasing their positions, 80 reducing their positions, and 39 closing their positions.
171% more call options, than puts
Call options by funds: $15.3M | Put options by funds: $5.63M
2.54% less ownership
Funds ownership: 109.5% → 106.96% (-2.5%)
5% less funds holding
Funds holding: 212 → 202 (-10)
16% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 80
23% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 39
25% less capital invested
Capital invested by funds: $3.94B → $2.94B (-$997M)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
+$45.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$25.6M |
| 3 |
AC
Armistice Capital
New York
|
+$20.6M |
| 4 |
BlackRock
New York
|
+$19.8M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$88.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$40.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$27.8M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$16.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$15.9M |
PTCT Hedge Fund Activity: Q4 2022 in Review
202 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2022, worth a combined $2.94B — down 25% from $3.94B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of PTCT and 30 opened new positions — a net loss of 9 holders — while 80 trimmed existing stakes and 67 added.
The largest buyer was Blackstone Inc, opening a new position worth an estimated $45.5M. The largest seller was Janus Henderson Group, cutting an estimated $88.5M.
- 202 institutional investors held PTC Therapeutics (PTCT) as of Q4 2022, down from 212 in Q3 2022.
- Funds reported $2.94B of PTC Therapeutics stock for Q4 2022, down 25% quarter-over-quarter.
- 30 funds opened new PTC Therapeutics positions in Q4 2022 and 39 closed out, a net change of -9 holders.
- The largest PTC Therapeutics buyer in Q4 2022 was Blackstone Inc, an estimated $45.5M added.
- The largest PTC Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $88.5M sold.
Based on aggregated 13F filings for Q4 2022.